Literature DB >> 22472951

A small-molecule-controlled system for efficient pseudotyping of prototype foamy virus vectors.

Yu-Ping Ho1, Viktor Schnabel, Anka Swiersy, Kristin Stirnnagel, Dirk Lindemann.   

Abstract

Foamy virus (FV) vector systems have recently demonstrated their power as efficient gene transfer tools for different target tissues. Unfortunately, FVs cannot be naturally pseudotyped by heterologous viral glycoproteins due to an unusual particle morphogenesis involving a FV Env-dependent particle release process. Therefore, current FV vector systems are constrained to the broad host cell range provided by the cognate viral glycoprotein. We evaluated different approaches for pseudotyping of FV vectors, in which the specific FV Gag-Env interaction, essential for particle egress, is substituted by a small-molecule controlled heterodimerization (HD) system. In one system developed, one HD-domain (HDD) is fused to a membrane-targeting domain (MTD), such as the human immunodeficiency virus (HIV) Gag matrix (MA) subunit, with a second fused to the FV capsid protein. Coexpression of both components with different heterologous viral glycoproteins allowed an efficient, dimerizer-dependent pseudotyping of FV capsids. With this system FV vesicular stomatitis virus glycoprotein (VSV-G) pseudotype titers greater than 1 × 10(6) IU/ml were obtained, at levels comparable to authentic FV vector particles. As a proof-of-principle we demonstrate that Pac2 cells, naturally resistant to FV vectors, become permissive to FV VSV-G pseudotypes. Similar to other retroviral vectors, this FV pseudotyping system now enables adaptation of cell-specific targeting approaches for FVs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22472951      PMCID: PMC3369295          DOI: 10.1038/mt.2012.61

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  30 in total

1.  Optimized large-scale production of high titer lentivirus vector pseudotypes.

Authors:  Miguel Sena-Esteves; Jessica C Tebbets; Sabine Steffens; Timothy Crombleholme; Alan W Flake
Journal:  J Virol Methods       Date:  2004-12-15       Impact factor: 2.014

2.  Prototype foamy virus envelope glycoprotein leader peptide processing is mediated by a furin-like cellular protease, but cleavage is not essential for viral infectivity.

Authors:  Anja Duda; Annett Stange; Daniel Lüftenegger; Nicole Stanke; Dana Westphal; Thomas Pietschmann; Scott W Eastman; Maxine L Linial; Axel Rethwilm; Dirk Lindemann
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 3.  Altering the tropism of lentiviral vectors through pseudotyping.

Authors:  James Cronin; Xian-Yang Zhang; Jakob Reiser
Journal:  Curr Gene Ther       Date:  2005-08       Impact factor: 4.391

4.  Correct capsid assembly mediated by a conserved YXXLGL motif in prototype foamy virus Gag is essential for infectivity and reverse transcription of the viral genome.

Authors:  Ingrid Mannigel; Annett Stange; Hanswalter Zentgraf; Dirk Lindemann
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

5.  Selective transduction of malignant glioma by lentiviral vectors pseudotyped with lymphocytic choriomeningitis virus glycoproteins.

Authors:  Hrvoje Miletic; Yvonne Heidemarie Fischer; Harald Neumann; Volkmar Hans; Werner Stenzel; Tsanan Giroglou; Manuel Hermann; Martina Deckert; Dorothee Von Laer
Journal:  Hum Gene Ther       Date:  2004-11       Impact factor: 5.695

6.  Mutations in the amino terminus of foamy virus Gag disrupt morphology and infectivity but do not target assembly.

Authors:  Rachel B Life; Eun-Gyung Lee; Scott W Eastman; Maxine L Linial
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

7.  Properties of human foamy virus relevant to its development as a vector for gene therapy.

Authors:  Claire L Hill; Paul D Bieniasz; Myra O McClure
Journal:  J Gen Virol       Date:  1999-08       Impact factor: 3.891

8.  In vitro cell-free conversion of noninfectious Moloney retrovirus particles to an infectious form by the addition of the vesicular stomatitis virus surrogate envelope G protein.

Authors:  A Abe; S T Chen; A Miyanohara; T Friedmann
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

9.  High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells.

Authors:  H Mochizuki; J P Schwartz; K Tanaka; R O Brady; J Reiser
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

10.  Foamy virus capsid assembly occurs at a pericentriolar region through a cytoplasmic targeting/retention signal in Gag.

Authors:  Shuyuarn F Yu; Scott W Eastman; Maxine L Linial
Journal:  Traffic       Date:  2006-06-02       Impact factor: 6.215

View more
  23 in total

1.  Advances in foamy virus vector technology and disease correction could speed the path to clinical application.

Authors:  Els Verhoeyen
Journal:  Mol Ther       Date:  2012-06       Impact factor: 11.454

2.  Prototype foamy virus protease activity is essential for intraparticle reverse transcription initiation but not absolutely required for uncoating upon host cell entry.

Authors:  Sylvia Hütter; Erik Müllers; Nicole Stanke; Juliane Reh; Dirk Lindemann
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

3.  In vivo fluorescence imaging and urinary monoamines as surrogate biomarkers of disease progression in a mouse model of pheochromocytoma.

Authors:  Martin Ullrich; Ralf Bergmann; Mirko Peitzsch; Marc Cartellieri; Nan Qin; Monika Ehrhart-Bornstein; Norman L Block; Andrew V Schally; Jens Pietzsch; Graeme Eisenhofer; Stefan R Bornstein; Christian G Ziegler
Journal:  Endocrinology       Date:  2014-08-19       Impact factor: 4.736

4.  Efficient transient genetic manipulation in vitro and in vivo by prototype foamy virus-mediated nonviral RNA transfer.

Authors:  Martin V Hamann; Nicole Stanke; Erik Müllers; Kristin Stirnnagel; Sylvia Hütter; Benedetta Artegiani; Sara Bragado Alonso; Federico Calegari; Dirk Lindemann
Journal:  Mol Ther       Date:  2014-05-12       Impact factor: 11.454

5.  Differential pH-dependent cellular uptake pathways among foamy viruses elucidated using dual-colored fluorescent particles.

Authors:  Kristin Stirnnagel; Dorothee Schupp; Aurélie Dupont; Volodymyr Kudryavtsev; Juliane Reh; Erik Müllers; Don C Lamb; Dirk Lindemann
Journal:  Retrovirology       Date:  2012-08-30       Impact factor: 4.602

Review 6.  Feline foamy virus-based vectors: advantages of an authentic animal model.

Authors:  Weibin Liu; Janet Lei; Yang Liu; Dragana Slavkovic Lukic; Ann-Mareen Räthe; Qiuying Bao; Timo Kehl; Anne Bleiholder; Torsten Hechler; Martin Löchelt
Journal:  Viruses       Date:  2013-07-12       Impact factor: 5.048

Review 7.  Foamy virus vectors for HIV gene therapy.

Authors:  Miles E Olszko; Grant D Trobridge
Journal:  Viruses       Date:  2013-10-22       Impact factor: 5.048

8.  Viral infiltration of pancreatic islets in patients with COVID-19.

Authors:  Charlotte Steenblock; Stefanie Richter; Ilona Berger; Marko Barovic; Janine Schmid; Undine Schubert; Natalia Jarzebska; Anne von Mässenhausen; Andreas Linkermann; Annette Schürmann; Jessica Pablik; Thomas Dienemann; Katja Evert; Roman N Rodionov; Natalia Y Semenova; Vsevolod A Zinserling; Raul R Gainetdinov; Gustavo Baretton; Dirk Lindemann; Michele Solimena; Barbara Ludwig; Stefan R Bornstein
Journal:  Nat Commun       Date:  2021-06-10       Impact factor: 14.919

9.  An N-terminal domain helical motif of Prototype Foamy Virus Gag with dual functions essential for particle egress and viral infectivity.

Authors:  Juliane Reh; Annett Stange; Anne Götz; Marlene Rönitz; Arend Große; Dirk Lindemann
Journal:  Retrovirology       Date:  2013-04-25       Impact factor: 4.602

10.  A unique spumavirus Gag N-terminal domain with functional properties of orthoretroviral matrix and capsid.

Authors:  David C Goldstone; Thomas G Flower; Neil J Ball; Marta Sanz-Ramos; Melvyn W Yap; Roksana W Ogrodowicz; Nicole Stanke; Juliane Reh; Dirk Lindemann; Jonathan P Stoye; Ian A Taylor
Journal:  PLoS Pathog       Date:  2013-05-09       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.